Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Nynomic verdoppelt: Geheimkunde Aixtron? Neuer Nvidia-Profiteur (Der Aktionaer) +++ NYNOMIC Aktie -4,82%

PFIZER Aktie

 >PFIZER Aktienkurs 
23.51 EUR    +0.7%    (TradegateBSX)
Ask: 23.51 EUR / 860 Stück
Bid: 23.485 EUR / 860 Stück
Tagesumsatz: 15206 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
PFIZER Aktie über LYNX handeln
>PFIZER Performance
1 Woche: +0,6%
1 Monat: +0,2%
3 Monate: +7,3%
6 Monate: +10,4%
1 Jahr: +20,0%
laufendes Jahr: +9,8%
>PFIZER Aktie
Name:  PFIZER INC. DL-,05
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US7170811035 / 852009
Symbol/ Ticker:  PFE (Frankfurt) / PFE (NYSE)
Kürzel:  FRA:PFE, ETR:PFE, PFE:GR, NYSE:PFE
Index:  S&P500
Webseite:  https://www.pfizer.com/
Profil:  Pfizer Inc. is a research-based global biopharmaceutical company founded in 1849 and headquartered in New York. It focuses on the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products worldwide, targeti..
>Volltext..
Marktkapitalisierung:  133261.72 Mio. EUR
Unternehmenswert:  179394.69 Mio. EUR
Umsatz:  53194.66 Mio. EUR
EBITDA:  20494.47 Mio. EUR
Nettogewinn:  6583.56 Mio. EUR
Gewinn je Aktie:  1.16 EUR
Schulden:  57306.31 Mio. EUR
Liquide Mittel:  970.75 Mio. EUR
Operativer Cashflow:  9949.72 Mio. EUR
Bargeldquote:  0.37
Umsatzwachstum:  -13.31%
Gewinnwachstum:  -14.88%
Dividende je Aktie:  1.47 EUR
Dividendenrendite:  6.24%
Dividendenschätzung:  6.28%
Div. Historie:  23.01.26 - 0.363694€
07.11.25 - 0.371649€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  PFIZER
Letzte Datenerhebung:  21.04.26
>PFIZER Kennzahlen
Aktien/ Unternehmen:
Aktien: 5688.36 Mio. St.
Frei handelbar: 99.9%
Rückkaufquote: -
Mitarbeiter: 75000
Umsatz/Mitarb.: 0.71 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 5.69%
Bewertung:
KGV: 20.25
KGV lG: 9.3
KUV: 2.47
KBV: 1.8
PEG-Ratio: -
EV/EBITDA: 8.75
Rentabilität:
Bruttomarge: 66.23%
Gewinnmarge: 12.38%
Operative Marge: 27.99%
Managementeffizenz:
Gesamtkaprendite: 3.67%
Eigenkaprendite: 8.87%
 >PFIZER Anleihen 
>PFIZER Peer Group
Gesundheit, Medizin für Bakterielle- & Pilzinfektionen/ Antibiotika, mRNA- Forschung/ Impfstoffe, Lungenerkrankungen & -behandlung/ Asthma, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Onkologie/ Krebs- Behandlung, Impfstoffentwicklung/ Impfstoffhersteller
 
20.04.26 - 21:21
Pfizer′s Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says (Reuters EN)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
20.04.26 - 14:06
Astellas, Pfizer Say FDA Grants Priority Review To SBLA For PADCEV Plus Keytruda (AFX)
 
TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) on Monday said the U.S. Food and Drug Administration has granted Priority Review for a supplemental Biologics License Applicati......
20.04.26 - 13:27
Pfizer, Astellas win FDA priority review for Padcev in bladder cancer with Merck’s Keytruda (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
20.04.26 - 09:18
Pfizer, Amgen among 22 firms to expand in Hong Kong: SCMP (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
18.04.26 - 18:24
Where Will Pfizer Stock Be in 3 Years? (Fool)
 
The healthcare giant has been investing heavily in its future growth....
17.04.26 - 16:24
AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit (24/7 Wall St.)
 
AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net sales with revenue up 10% year over year, powered by a post-Humira immunology rebuild that is now clearly working. Pfizer posted a slight revenue decline of 1.16% while absorbing a massive COVID hangover and betting billions on obesity ... AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit...
16.04.26 - 14:00
Here Are Thursday′s Top Wall Street Analyst Research Calls: Autoliv, CoreWeave, Corning, Dicks Sporting Goods, Federated Hermes, Gitlab, PayPal, Pfizer, Okta, and More (24/7 Wall St.)
 
Pre-Market Stock Futures: The futures are trading modestly higher after a wild Wednesday that saw the Nasdaq explode higher to close at an all-time high of 24,016, up a hefty 1.60%, while the S&P 500 closed up 0.80% at 7,022, also hitting a brand-new all-time closing high. The small-cap Russell 2000, the leading index this ... Here Are Thursday's Top Wall Street Analyst Research Calls: Autoliv, CoreWeave, Corning, Dicks Sporting Goods, Federated Hermes, Gitlab, PayPal, Pfizer, Okta, and More...
14.04.26 - 15:06
Build a Six Figure Dividend Stream With Four Blue Chip Names and $2 Million (24/7 Wall St.)
 
Two million dollars in four household-name dividend payers can generate between $132,000 and $146,000 in annual income. That is the income profile of the moderate yield tier, where Enterprise Products Partners L.P. (NYSE:EPD), Pfizer Inc. (NYSE:PFE), Altria Group (NYSE:MO), and Verizon Communications (NYSE:VZ) currently sit. The real question is whether $2 million is right for ... Build a Six Figure Dividend Stream With Four Blue Chip Names and $2 Million...
14.04.26 - 15:00
Pfizer: Wie ein Apotheker und ein Konditor den US-Pharma-Giganten gründeten (WiWo)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
14.04.26 - 14:06
Four Tickers That Turn $1 Million Into $60,000 of Annual Income (24/7 Wall St.)
 
A million dollars sounds like enough to retire on. Whether it actually is depends entirely on what you make it do. At a blended yield of roughly 6%, $1,000,000 produces exactly $60,000 per year in investment income. Four tickers currently sitting in that yield range are Pfizer Inc (NYSE:PFE), Altria Group (NYSE:MO), Verizon Communications Inc ... Four Tickers That Turn $1 Million Into $60,000 of Annual Income...
14.04.26 - 01:57
Biden FDA Knew About COVID Vaccine Stroke Risk And Kept Americans In The Dark (ZeroHedge)
 
Biden FDA Knew About COVID Vaccine Stroke Risk And Kept Americans In The Dark Senate investigators spent months reviewing roughly 2,000 pages of federal records. What they found is damning. FDA and CDC officials under the Biden administration identified a significant stroke risk tied to Pfizer's COVID-19 bivalent booster in seniors - and never breathed a word to the public. Sen. Ron Johnson (R-WI), chairman of the Senate's Permanent Subcommittee on Investigations, sent a formal letter to HHS Secretary Robert F. Kennedy Jr. laying out the evidence. He wasn't speculating. He was citing the government's own files. "HHS records show that as early as October 2022, federal health officials identified a potential connection between the Pfizer-BioNTech COVID-19 bivalent booster and ischemic stroke for individuals over the age of 65," Johnson wrote. An ischemic stroke means a blockage of blood to the brain. Between November 2022 and March 2023, seven separate analyses of incoming data fla...
14.04.26 - 01:00
Pfizer (PFE) Outperforms Broader Market: What You Need to Know (Zacks)
 
Pfizer (PFE) reached $27.34 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close....
13.04.26 - 13:33
Frontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of Directors (Business Wire)
 
Mr. Epstein brings more than 30 years of global drug development and commercialization experience to support Frontier's next phase of growth as it continues to advance its pipeline of covalent precision medicines BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced the appointment of David R. Epstein to its board of directors. Mr. Epstein currently serves as chairman and chief executive officer of Ottimo Pharma and was most recently chief executive officer of Seagen, where he led the company through a period of significant growth and innovation, culminating in its acquisition by Pfizer in 2023. “David is a transformative leader with an exceptional track record of building and scaling innovative biopharmaceutical organizations,” said Chris Varma, Ph.D., co-founder, chairman, ...
13.04.26 - 13:12
Trellus Health signs renewal of licensing deal with Pfizer (Alliance)
 
Trellus Health PLC on Monday said it signed a renewal of its licensing agreement with New York-based pharmaceutical company...
13.04.26 - 10:36
Trellus Health shares jump 39% on Pfizer deal renewal (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
12.04.26 - 09:15
Pfizer: Wie ein Apotheker und ein Konditor den US-Pharmagiganten gründeten (WiWo)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
12.04.26 - 07:36
Better Buy Right Now: Johnson & Johnson Vs. Pfizer (Fool)
 
The choice is based on more than just the dividend payout....
10.04.26 - 18:15
Here′s How AMRX Is Tapping GLP-1 Demand Through Manufacturing (Zacks)
 
Amneal Pharmaceuticals taps GLP-1 growth via a Pfizer-linked manufacturing deal, gaining exposure without clinical risks while scaling injectables and peptides....
10.04.26 - 08:18
Pfizer Neutral (DPA-AFX)
 
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Chris Schott sieht für die Ziele des Pharmaherstellers Luft nach oben, wie er am Donnerstag in seinem Ausblick ......
09.04.26 - 16:06
Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders (Business Wire)
 
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT. Shareholders can find information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2026. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control number found on their proxy card, voting instruction form or the notice that was previously received. Only shareholders who log into the meeting using a control number will have the ability to ask questions or vote during the live meeting. No control number is required to participate in a listen-only mode. Registered and most beneficial shareholders can vote during the meeting by following the instructions provided on the “Rules of Conduct and Meeting Procedures” available on the virtual meeting platform. Some benefici...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Quid sit futurum cras, fuge quaerere! - Forsche nicht danach, was morgen sein wird! - Quintus Flaccus Horaz
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!